|
|
Thomas J. Kelley, Heather L. Elmer
J Clin Invest. 2000;
106(3):403
doi:10.1172/JCI9560
Abstract |
Full text
| PDF

I
nducible nitric oxide synthase-2 (NOS2) expression has been shown to be reduced in cystic fibrosis (CF) epithelial cells. Reduced NOS2 expression is unexpected, given the inflammatory nature of CF airway disease, and is an indication that cell-signaling mechanisms necessary for proper NOS2 regulation are probably altered in CF epithelium. Therefore, we examined the expression levels of regulatory factors necessary for NOS2 expression in CF epithelium and showed that IFN regulatory factor-1 (IRF-1) is necessary for full NOS2 expression. Mice lacking IRF-1 expression have diminished epithelial NOS2 expression, as well as reduced NO-dependent chloride transport across the nasal epithelia. Furthermore, IRF-1 protein expression is reduced in nasal and intestinal epithelial cells from CF mice, suggesting a possible mechanism for the CF-related reduction of epithelial NOS2 expression. Active signal transducer and activator of transcription-1 (Stat1) is necessary for both NOS2 and IRF-1 expression. We found that protein levels of Stat1 were increased in CF cells, but that the active phosphorylated form of Stat1 was bound to the protein inhibitor of activated Stat1 (PIAS1). We propose that increased levels of PIAS1 diminish certain cell-signaling pathways, resulting in reduced IRF-1 and NOS2 expression in CF epithelial cells.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
About CrossRef
| Title and authors |
Publication |
Year |
. |
Pathway prediction by bioinformatic analysis of the untranslated regions of the CFTR mRNA
Jean Spence |
Physiol Genomics |
2009 |
.
|
Anti-inflammatory Therapies for Cystic Fibrosis-Related Lung Disease
David P. Nichols, Michael W. Konstan, James F. Chmiel |
CRIAI |
2008 |
.
|
Chronic Inflammation in the Cystic Fibrosis Lung: Alterations in Inter- and Intracellular Signaling
David Nichols, James Chmiel, Melvin Berger |
CRIAI |
2007 |
.
|
Respiratory syncytial virus infection in a murine model of cystic fibrosis
Giuseppe N. Colasurdo, Jason J. Fullmer, Okan Elidemir, Constance Atkins, Amir M. Khan, James M. Stark |
J Med Virol |
2006 |
.
|
Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study of Aerosolized Interferon Gamma-1b in Patients With Mild to Moderate Cystic Fibrosis Lung Disease
Richard B. Moss, Nicole Mayer-Hamblett, Jeffrey Wagener, Cori Daines, Kathryn Hale, Richard Ahrens, Ronald L. Gibson, Paula Anderson, George Retsch-Bogart, Samya Z. Nasr, Imre Noth, David Waltz, Pamela Zeitlin, Bonnie Ramsey, Karen Starko |
Pediat Pulmonol |
2005 |
.
|
|
|
|